SCM
SPRO icon

Stonepine Capital Management’s Spero Therapeutics SPRO Stock Holding History

Stonepine Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-156,888
Closed -$455K – 73
2025
Q2 		$455K Buy
+156,888
New +$226K 0.45% 41
2018
Q4 		– Sell
-226,444
Closed -$2.38M – 27
2018
Q3 		$2.38M Buy
+226,444
New +$2.63M 1.39% 21

Other funds holding SPRO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonepine Capital Management's SPRO Position: Q3 2025 in Review

Stonepine Capital Management sold out of Spero Therapeutics (SPRO) in Q3 2025, closing a stake of 156,888 shares — an estimated $455K sold.

Stonepine Capital Management first reported a position in SPRO in Q3 2018 and held it in 2 quarters. The position peaked at $2.38M in Q3 2018. 47 funds tracked by Wall St. Rank hold SPRO as of Q3 2025.

  • Stonepine Capital Management reported no remaining Spero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 156,888 Spero Therapeutics shares in Q3 2025, an estimated $455K.
  • Stonepine Capital Management first reported a position in Spero Therapeutics in Q3 2018 and held it in 2 quarters.
  • Stonepine Capital Management's Spero Therapeutics position peaked at $2.38M in Q3 2018.
  • 47 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2025.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.